Review Board) , 2) the Childrens Hospital Los Angeles 
Institutional Biosafety Committee, 3) the Recombinant Advisory 
Committee (RAC) at the NIH, and 4) the Food and Drug 
Administration (FDA) . The approval of these committees does not 
alter the fact that the final decision to enter yourself in the 
study program is yours. You understand that you have the right 
to remove yourself from the study at any time. Dr. Lenarsky or 
Dr. Kohn will answer any questions you may have regarding this 
study. Subsequent medical care of yourself at the Childrens 
Hospital Los Angeles is in no way contingent upon your 
participation in this study program. 
HOW TO OBTAIN INFORMATION 
Daytime Monday through Friday, 8 AM to 5 PM, you may call 
(213) 669-2646. You may leave a message with a secretary, and a 
doctor will return your call. Evening, nighttime, and weekends 
or holidays: You may call the hospital number (213) 660-2450, 
and ask for the on-call doctor for the Bone Marrow Transplant 
Service. You may be asked to leave a message with the page 
operator, and the physician on-call will return your call as soon 
as possible. 
If you have any questions regarding your rights as a patient 
with regard to this study program, you can contact Ms. Gwenn Oki, 
Administrator of the Committee on Clinical Investigations (IRB) 
at (213) 669-2265. 
[846] 
Recombinant DNA Research, Volume 17 
